These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 24757111)

  • 21. Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease.
    Bäckström D; Eriksson Domellöf M; Granåsen G; Linder J; Mayans S; Elgh E; Zetterberg H; Blennow K; Forsgren L
    Acta Neurol Scand; 2018 Jan; 137(1):91-98. PubMed ID: 28869277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.
    Fagan ES; Pihlstrøm L
    Eur J Neurol; 2017 Apr; 24(4):561-e20. PubMed ID: 28220571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers for cognitive impairment in Parkinson disease.
    Shi M; Huber BR; Zhang J
    Brain Pathol; 2010 May; 20(3):660-71. PubMed ID: 20522092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].
    Mollenhauer B; Sixel-Döring F; Storch A; Schneider C; Hilker R; Kalbe E
    Nervenarzt; 2013 Aug; 84(8):918-26. PubMed ID: 23831930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
    Hirano S; Shinotoh H; Eidelberg D
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical workout for the early detection of cognitive decline and dementia.
    Tsolaki M
    Eur J Clin Nutr; 2014 Nov; 68(11):1186-91. PubMed ID: 25271010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease.
    Lin CH; Fan JY; Lin HI; Chang CW; Wu YR
    Parkinsonism Relat Disord; 2018 May; 50():48-53. PubMed ID: 29439855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurobiology of cognitive impairment in Parkinson's disease.
    Jellinger KA
    Expert Rev Neurother; 2012 Dec; 12(12):1451-66. PubMed ID: 23237352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.
    Leaver K; Poston KL
    Neuropsychol Rev; 2015 Dec; 25(4):411-23. PubMed ID: 26626621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.
    Chahine LM; Dos Santos C; Fullard M; Scordia C; Weintraub D; Erus G; Rosenthal L; Davatzikos C; McMillan CT
    Eur J Neurol; 2019 Feb; 26(2):246-e18. PubMed ID: 30169897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
    Aarsland D
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S144-8. PubMed ID: 26411499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of cognitive decline in PD: The case for heterogeneity.
    Monchi O; Hanganu A; Bellec P
    Parkinsonism Relat Disord; 2016 Mar; 24():8-14. PubMed ID: 26774536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies.
    Burn DJ; Rowan EN; Allan LM; Molloy S; O'Brien JT; McKeith IG
    J Neurol Neurosurg Psychiatry; 2006 May; 77(5):585-9. PubMed ID: 16614017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.